Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $2.45M | $8.55M | $0.00 |
| Revenue growth | — | — | — | — | — | 249.5% | -100.0% |
| Operating income | -$35.8M | -$62.0M | -$167M | -$215M | -$126M | -$200M | -$326M |
| Operating margin | — | — | — | — | -5164.4% | -2340.3% | — |
| Net income | -$35.5M | -$61.8M | -$167M | -$214M | -$123M | -$183M | -$303M |
| Net margin | — | — | — | — | -5037.9% | -2137.5% | — |
| EPS (diluted) | -$26.60 | -$7.86 | -$3.94 | -$69.65 | -$18.69 | -$10.21 | -$13.48 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.4M | -$52.6M | -$125M | -$185M | -$111M | -$132M | -$249M |
| Capital expenditures | $103K | $0.00 | $1.05M | $444K | $50.0K | $0.00 | $56.0K |
| Free cash flow | -$33.5M | -$52.6M | -$126M | -$185M | -$111M | -$132M | -$249M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $44.8M | $297M | $139M | $61.6M | $81.3M | $215M | $357M |
| Total assets | $47.7M | $303M | $293M | $115M | $87.9M | $483M | $938M |
| Total liabilities | $7.58M | $15.7M | $41.9M | $39.0M | $18.3M | $37.7M | $59.8M |
| Shareholders' equity | -$81.0M | $287M | $251M | $76.1M | $69.7M | $445M | $878M |
| Retained earnings | -$81.0M | -$150M | -$317M | -$531M | -$654M | -$837M | -$1.14B |
| Shares (wtd avg diluted) | 1.62M | 8.95M | 42.5M | 3.07M | 6.59M | 17.9M | 22.5M |
Every figure is extracted from Praxis Precision Medicines, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.